Promaxo is at the forefront of transforming prostate cancer care through its innovative MRI system, which integrates advanced imaging, artificial intelligence (AI), and robotics. The Promaxo MRI System is designed for in-office use, allowing urologists to perform MRI-targeted prostate biopsies and treatments with enhanced precision and confidence. This system boasts a unique single-sided design that facilitates easy access and installation in various clinical settings, eliminating the need for major facility upgrades. With a reported cancer detection rate of 77%, the Promaxo MRI System significantly improves the identification of clinically significant cancers compared to standard care practices.

The technology leverages proprietary imaging techniques and AI algorithms to create detailed 3D visualizations, enabling real-time intraoperative planning and guidance. Additionally, the Promaxo Robot, which is still under development, aims to further enhance the accuracy and efficiency of prostate interventions by automating procedures based on real-time imaging data. This combination of advanced imaging and robotic assistance positions Promaxo as a leader in precision diagnostics and treatment, ultimately aiming to provide personalized care tailored to individual patient needs.

United States

Promaxo is a medical technology company that develops and commercializes customer-centric MRI systems and MRI based technologies that enhance patients' experiences and outcomes. The Promaxo MRI system is designed for image-guided interventions including live MRI guided biopsies, treatment planning, robotic surgeries, and radiation.

Promaxo

Company Details